The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report (Q41883212)

13 October 2017

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report (English)

1 reference

13 October 2017

1 reference

14

1 reference

13 October 2017

5

Peter F Ambros

0 references

Susan L. Cohn

1

object named as

Susan L Cohn

0 references

Alberto Garaventa

object named as

Alberto Garaventa

13

0 references

author name string

Andrew D J Pearson

2

1 reference

13 October 2017

Wendy B London

3

1 reference

13 October 2017

Tom Monclair

4

1 reference

13 October 2017

Garrett M Brodeur

6

1 reference

13 October 2017

Andreas Faldum

7

1 reference

13 October 2017

Barbara Hero

8

1 reference

13 October 2017

Tomoko Iehara

9

1 reference

13 October 2017

David Machin

10

1 reference

13 October 2017

Veronique Mosseri

11

1 reference

13 October 2017

Thorsten Simon

12

1 reference

13 October 2017

Katherine K Matthay

15

1 reference

13 October 2017

INRG Task Force

16

1 reference

13 October 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

Journal of Clinical Oncology

13 October 2017

1 reference

13 October 2017

27

1 reference

13 October 2017

289-297

1 reference

13 October 2017

2

1 reference

Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Chromosome 1p and 11q deletions and outcome in neuroblastoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Neuroblastoma: biological insights into a clinical enigma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Prognostic significance of DNA di-tetraploidy in neuroblastoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

The International Neuroblastoma Pathology Classification (the Shimada system).

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Hyperdiploidy Plus NonamplifiedMYCNConfers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study

2 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

2 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2650388

Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group

2 December 2018

1 reference

12 December 2020

1 reference

12 December 2020

Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma

1 reference

12 December 2020

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

1 reference

12 December 2020

Exponential survival trees

1 reference

12 December 2020

Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study

1 reference

12 December 2020

The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group

1 reference

12 December 2020

Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma

1 reference

12 December 2020

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2008.16.6785

1 reference

13 October 2017

1 reference

13 October 2017

1 reference